Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Saskatchewan company fined after wash bay attendant pinched between vehicles

October 9, 2026

Google teases Fitbit Edge launch next week

October 9, 2026

Okanagan growers say crop insurance isn’t keeping up with a changing climate

October 9, 2026

1 in 3 young Canadians use AI once a month for mental health, report shows

October 9, 2026

Nikon microscopic video competition winner disqualified for using generative AI

October 9, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Press Release

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

By News RoomJune 9, 20262 Mins Read
Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.
Share
Facebook Twitter LinkedIn Pinterest Email

BEDMINSTER, N.J., June 09, 2026 (GLOBE NEWSWIRE) — Alembic Therapeutics, LLC announces the acquisition of NUVESSA® (metronidazole vaginal gel 1.3%), an FDA-approved prescription medication indicated for the treatment of bacterial vaginal infections in females 12 years of age and older, from Exeltis USA, Inc. This acquisition represents an important milestone in Alembic Therapeutics’ ongoing commitment to expanding its women’s health portfolio and increasing patient access to proven treatment options. Through this transaction, Alembic Therapeutics assumes responsibility for the commercialization and distribution of NUVESSA in the United States.

NUVESSA is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. NUVESSA is designed as a convenient single-dose, pre-filled disposable applicator, which delivers approximately 5g of gel containing 65mg of metronidazole, administered once a day at bedtime intravaginally. NUVESSA is contraindicated in persons who have shown hypersensitivity to metronidazole, parabens, any component of the formulation, or other nitroimidazole derivatives.

NUVESSA will continue to be available nationwide through retail and specialty pharmacy distribution channels. Healthcare providers can continue prescribing NUVESSA in accordance with the approved prescribing information for appropriate patients. The full prescribing information should be consulted for complete details regarding approved indications, dosing, administration, contraindications, warnings, and safety information.

Alembic Therapeutics is dedicated to delivering high-quality pharmaceutical products and innovative healthcare solutions that improve patient outcomes and expand access to care across multiple therapeutic categories.

Alembic Therapeutics, LLC
550 Hills Drive, Suite 110
Bedminster NJ 07921
908-569-7456 • [email protected]
www.alembictherapeutics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c2b9304-e79b-43e8-8e2c-9cb1ad8774ae

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

vineyard vines Returns as Official Style of the Head Of The Charles® Regatta

Bigger & Better Than Ever: Laxmi & Chef Kunal Kapur Return With ‘Diwali Delights’ Season 2

2026 Chery International User Summit to Kick Off: LUXEED Set for Global Brand Launch

Going Asset Management Wins Capital’s Excellence Fund Award, Harnessing Technology to Enhance the Long-Term Value of Assets

Alation Honors 2026 AI Radicals Award Winners at revAlation

Supported Employment: Helping Individuals Build Meaningful Careers

“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity

Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to 11 Million and Reaffirms 460 Million Fiscal 2027 Outlook

Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading

Editors Picks

Google teases Fitbit Edge launch next week

October 9, 2026

Okanagan growers say crop insurance isn’t keeping up with a changing climate

October 9, 2026

1 in 3 young Canadians use AI once a month for mental health, report shows

October 9, 2026

Nikon microscopic video competition winner disqualified for using generative AI

October 9, 2026

Latest News

Bank of Canada says aging population, low immigration ‘reshaping’ economy

October 9, 2026

Amazon’s new Kindles appear to have a light leak problem

October 9, 2026

Police investigate small plane crash in field near Fergus, Ont.

October 9, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version